ArticleLangenbeck's archives of surgery2025
A prognostic score based on early recurrence-related factors for hepatocellular carcinoma patients with microvascular invasion after hepatectomy.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Satellite Lesions in Hepatocellular Carcinoma: An Updated Review.Journal of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeWe aimed to construct a simple risk score to stratify individuals with distinguished prognosis for HCC patients with microvascular invasion (MVI).
methods265 qualified patients were retrospectively analyzed. A prognostic score was constructed using predictors associated with early recurrence (ER). Based on the HR value, AFP > 400 ng/ml and hepatitis B viral e antigen (HBeAg) positivity were assigned as 1 point, satellite nodule was assigned 2 points. There were five subgroups (score 0/1/2/3/4). Due to similar RFS in score 2/3/4 subgroups, we merged these into a single cohort (group C), while maintaining score 0 as group A and score 1 as group B.
resultsMVI (+) HCC patients who developed ER had dramatically decreased overall survival (OS) compared with those who did not(P < 0.001). Based on the result of multivariable analysis, MVI (+) HCC patients with satellite nodules, positive HBeAg or serum alpha-fetoprotein above 400ng/ml were more likely to developed ER. The 3-year recurrence free survival rates for the group A, group B and group C were 42.7%, 26.4% and 9.3%, respectively. The 3-year OS rates for group A, group B and group C were 65.4%, 48.7% and 26.9%, respectively (p < 0.001). A higher score was correlated with significantly worse prognosis (p < 0.001). Furthermore, the prognostic score distinguished the prognosis of MVI (+) HCC patients independently of liver cirrhosis (p < 0.001).
conclusionsThe prognostic score consisted of ER-related factors effectively predict prognosis for MVI (+) HCC patients after hepatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.